Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lanreotide + metformin
- Development stage
- Phase 1
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous, Oral
01
Overview
A combination therapy consisting of lanreotide, a somatostatin analog, and metformin, an antidiabetic medication. This combination has shown promising antitumor activity in both diabetic and non-diabetic patients with well-differentiated neuroendocrine tumors (WDNETs) of the gastrointestinal or thoracic tract. The MetNET-2 trial demonstrated that this combination is safe and well-tolerated with a median progression-free survival of 24 months.
- Other names
- Lanreotide and MetforminLanreotide 120 mg ATG + Metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)SSTR2 (Somatostatin receptor type 2)SSTR5 (Somatostatin receptor 5)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on lanreotide + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lanreotide + metformin.